Qurio Pte Ltd – Trademark Portfolio
Entity Type: 99
Qurio Pte Ltd holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include CERM, INVITY, and XANDRO. The owner is based in Singapore.
8 Kaki Bukit Ave 1 #02-01
Singapore 417941 , SG
Showing of trademarks Trademarks
Trademark Classifications
Qurio Pte Ltd's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Leather and imitations of leather; animal skins, hides; trunks and travelling bags
Frequently Asked Questions
How many trademarks does Qurio Pte Ltd have?
Qurio Pte Ltd has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned.
What trademark classes does Qurio Pte Ltd file in?
Qurio Pte Ltd files trademarks across 4 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 35 (Advertising & Business), Class 18 (Leather Goods). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Qurio Pte Ltd's most well-known trademarks?
Qurio Pte Ltd's registered trademark portfolio includes well-known marks such as CERM, INVITY, and XANDRO. These are among 3 currently registered trademarks in the portfolio.
What is Qurio Pte Ltd's trademark registration success rate?
Qurio Pte Ltd has a 43% trademark registration rate, with 3 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.